Here, the group of patients receiving InO who had higher lymphoma cell CD22 expression (with a central laboratory-adjudicated immunohistochemical staining intensity H-score of ≥100/300, with score values ranging from 0 [no staining] to 300 [strong staining]) had nonsignificantly prolonged survival compared to those receiving InO with lower CD22 expression (H-score of < 100/300). Here, CD22 is linked to lymphoma.